Earnings Releases·Oct 29, 2026, 7:06 AM ET

West Pharmaceutical Services — Third Quarter 2026 Earnings Summary

Net sales reached $874.5 million (up 8.7% YoY, 11.9% organic), while diluted EPS rose 57.3% YoY to $3.02 and adjusted diluted EPS increased 35.7% YoY to $2.66.
Full-year 2026 guidance was raised for net sales ($3.41–$3.42 billion vs. $3.345–$3.380 billion) and adjusted diluted EPS ($9.38–$9.48 vs. $8.85–$9.05), with capital spending guidance reduced to $215–$220 million.
The company repurchased $231 million of stock in the quarter (bringing YTD total to $685 million) and declared a Q4 dividend of $0.26 per share, an 18% increase.
Strategic M&A activity included the sale of SmartDose® 3.5mL assets to AbbVie, generating a $55.7 million net gain and $54.0 million net benefit, with no further sales of this product expected for the remainder of 2026.
High-Value Product (HVP) Components drove growth with 19.7% YoY sales increase, while the West Vantage segment declined 7.3% YoY; Asia Pacific reported the strongest regional growth at 42.4%.